Azacitidine is used to treat patients with myelodysplastic syndromes.
阿扎胞苷用于治疗患有骨髓增生异常综合症的患者。
How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic Syndromes.
多大剂量？多少频率？多长时间？骨髓增生异常综合征新疗法的临床应用指南。
Objective To explore the value of immunocytochemistry in diagnosis of myelodysplastic syndromes( MDS).
目的探讨免疫细胞化学法在骨髓增生异常综合征（MDS）诊断价值。
We performed a study on efficacy and safety of bortezomib as a single agent in patients with myelodysplastic syndromes (MDS).
我们研究了硼替佐米单药在骨髓增生异常综合征中应用的有效性和安全性。
Procarbazine, nitrogen mustard, and ifosfamide, which can increase risk for myelodysplastic syndromes and acute myelogenous leukemia.
丙卡巴肼、氮芥和异环磷酰胺：可增加患骨髓增生异常综合症和急性粒细胞白血病的风险。
Azacitidine is used to treat patients with myelodysplastic syndromes (usually abbreviated, a bit oddly, to MDS), a group of rare and deadly blood malignancies.
氮杂胞苷（Azacitidine），用于治疗骨髓增生异常综合征（MDS）一种罕见的恶性血液肿瘤。
New drugs and new combinations of therapies are needed to further improve outcomes and find cures for individuals with leukemia, lymphoma and myelodysplastic syndromes.
我们需要新药和新的综合疗法来进一步改善治疗结果，并找寻针对白血病，淋巴瘤，骨髓增生异常综合症的治疗方法。
Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.
Revlimid和类固醇地塞米松联合用药被批准用于多发性脊髓瘤和罕见病骨髓增生异常综合征 的治疗。 其2009年的销售额为17亿美元。
Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.
Revlimid和类固醇地塞米松联合用药被批准用于多发性脊髓瘤和罕见病骨髓增生异常综合征 的治疗。 其2009年的销售额为17亿美元。
应用推荐